OptiBiotix Health PLC Distribution agreement for LPLDL® in Japan (5500P)
11 February 2019 - 6:00PM
UK Regulatory
TIDMOPTI
RNS Number : 5500P
OptiBiotix Health PLC
11 February 2019
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Distribution agreement for Lactobacillus plantarum LP(LDL) (R)
in Japan
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, cardiovascular disease and
diabetes, announces that its fully-owned subsidiary ProBiotix
Health Ltd., has appointed EIWA Trading Co. Ltd. ("EIWA") as its
exclusive distributor for LP(LDL) (R) in Japan.
The agreement grants EIWA the exclusive rights to import, market
and distribute OptiBiotix's cholesterol and blood pressure-reducing
probiotic strain Lactobacillus plantarum LP(LDL) (R) in Japan for a
period of three years. Market exclusivity is linked to increasing
minimum annual volumes in order to maximise the financial return
for both parties providing some surety of income for OptiBiotix
over the next three years.
Based in Japan, EIWA was founded in 1963 as a distributor of
food ingredients and flavours. It started its operations in
functional ingredients 25 years ago and has been a major player in
probiotics distribution in the country for the last ten years,
servicing both food, dairy and food supplements companies. This
agreement creates opportunities for EIWA to market LP(LDL) (R) for
use as a food and dairy ingredient as well as a food
supplement.
Asia-Pacific is currently the main market for probiotics
(Euromonitor, 2018), and Japan accounts for 45% of it. In Japan,
dairy probiotic applications are culturally very well established
and their market is forecasted to grow with a sizeable CAGR of 14%
until 2023. Probiotic food supplements have been gaining
significant momentum over the last number of years and their market
growth rates are expected to outpace those of dairy probiotic
products in the abovementioned period (Research and Markets,
2018).
Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to
announce this distribution agreement with EIWA. This deal provides
OptiBiotix market access in Japan, the main national market for
probiotics within the largest region for probiotics in the world.
We have chosen EIWA as they are a well-known and respected provider
of probiotics to the Japanese food, dairy and supplement
industries, creating the potential to extend the use of LP(LDL) (R)
beyond supplements in a major international market. This agreement
is another step in OptiBiotix's strategy of building revenues and
market presence of LP(LDL) (R) as the 'Intel' inside a wide range
of food, dairy and supplement products around the world. We believe
working with EIWA and similar partners around the world will
provide the best opportunity of rapidly building LP(LDL) (R) into a
valuable global brand."
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cairn Financial Advisers LLP (NOMAD)
Liam Murray / Jo Turner Tel: 020 7213 0880
finnCap (Broker)
Geoff Nash/ Scott Mathieson / Kate Bannatyne
(Corporate Finance) Tel: 020 7220 0500
Camille Gochez (Corporate Broking)
Walbrook PR Ltd Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D program working with leading
academics in the development of microbial strains, compounds, and
formulations which are used as active ingredients and supplements.
More than twenty international food and healthcare supplement
companies have signed agreements with OptiBiotix to incorporate
their human microbiome modulators into a wide range of food
products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
AGRTPMFTMBMMBJL
(END) Dow Jones Newswires
February 11, 2019 02:00 ET (07:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2024 to May 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From May 2023 to May 2024